Primaa, a French AI healthtech startup transforming digital pathology and cancer diagnostics, has raised €7 million in an extended funding round to accelerate product development and international expansion.
The round was supported by MH Innov’, Elaia’s partnership fund, SWEN Capital Partners, Super Capital, and members of the Wendel family.
Bringing Automation and Precision to Cancer Diagnostics
Founded in Paris, Primaa develops AI-powered software that automates key stages of histological analysis — the microscopic study of tissue — to help pathologists detect and quantify cancer biomarkers more efficiently.
Its flagship product, Cleo Breast (CE-IVDR certified), assists in identifying and measuring biomarkers in breast cancer tissue, while Cleo Skin, currently under CE marking, focuses on skin cancers such as melanoma, squamous cell carcinoma, and basal cell carcinoma.
“Our tools make diagnostics not only faster and more reliable, but also far less burdensome for medical teams,” said Fanny Sockeel, CEO and Co-founder of Primaa. “By automating detection and counting, we remove repetitive tasks so specialists can focus on what truly matters — patient care.”
Advertisement
Rapid Adoption Across Leading European Hospitals
Primaa’s technology is already in use across major healthcare institutions in France, including Institut Curie, AP-HP, and Saint-Joseph Hospital, and is expanding into Europe with partners such as ZAS Laboratory (Czech Republic) and Liège University Hospital (Belgium).
The company is also developing new AI modules for cervical cancer (with AP-HP and Medipath) and prostate cancer (with Erasme Hospital, Belgium).
Fueling Growth and U.S. Expansion
The fresh €7 million in funding will be used to:
- Strengthen commercial operations and accelerate European rollout
- Expand customer support and integration capabilities
- Advance predictive AI models for tracking disease progression and relapse risk
- Support FDA certification and market entry in the United States
“Primaa’s technology is at the intersection of AI and medical imaging, offering real-world clinical impact,” said a spokesperson from Elaia. “Their solutions empower pathologists and hospitals to deliver faster, more consistent diagnoses.”
About Primaa
Primaa is a Paris-based AI healthtech company developing software that automates and enhances histological and cancer diagnostics. Its tools leverage advanced machine learning to detect key biomarkers, improve diagnostic precision, and reduce workloads for pathologists. By combining medical expertise with cutting-edge AI, Primaa aims to make cancer diagnostics faster, more accurate, and globally accessible.
